Skip to main content
SpringerLink
Log in

Immunomodulators and Autoimmune Liver Diseases

  • Chapter
  • First Online:
Immunomodulators and Human Health

  • 496 Accesses

Abstract

Autoimmune liver disease (AiLD) is a series of progressive and chronic inflammation of the bile duct and liver cells arising due to impaired coordination between the components of one’s immune systems ultimately leading to the destruction of the liver. This disease primarily constitutes autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) under its wing. Immunomodulatory therapy established itself as a robust approach by providing a platform to treat such diseases. Although tremendous efforts have been put forth for instituting immunomodulatory therapy for PSC, the lack of positive results in a majority of the experimental studies prevailed with intense research is currently underway. This chapter unfolds with a brief perspective on the epidemiological, pathogenetic and clinical studies of AiLDs and dives deep into understanding the intricate dynamics of immune response during the pathogenesis of AIH. This study also highlights the numerous immunomodulators emphasizing its therapeutic potential for treating AiLDs.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F (2013) The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol:593–608

    Google Scholar 

  • Bowlus CL, Gershwin ME (2014) The diagnosis of primary biliary cirrhosis. Autoimmun Rev 13(4–5):441–444

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Broering R, Lu M, Schlaak JF (2011) Role of toll-like receptors in liver health and disease. Clin Sci 121:415–426

    Article  CAS  Google Scholar 

  • Burak KW, Swain MG, Santodomingo-Garzon T, Lee SS, Urbanski SJ, Aspinall AI, Coffin CS, Myers RP (2013) Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy. Can J Gastroenterol 27(5):273–280

    Article  PubMed  PubMed Central  Google Scholar 

  • Corpechot C, Carrat F, Bahr A, Chrétien Y, Poupon RE, Poupon R (2005) The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 128(2):297–303

    Article  CAS  PubMed  Google Scholar 

  • Cuperus FJC, Halilbasic E, Trauner M (2014) Fibrate treatment for primary biliary cirrhosis. Curr Opin Gastroenterol 30(3):279–286

    Article  PubMed  Google Scholar 

  • Czaja AJ (2011a) Drug-induced autoimmune-like hepatitis. Dig Dis Sci 56:958–976

    Article  CAS  PubMed  Google Scholar 

  • Czaja AJ (2011b) Performance parameters of the conventional serological markers for autoimmune hepatitis. Dig Dis Sci 56:545–554

    Article  CAS  PubMed  Google Scholar 

  • Czaja AJ (2013) Autoimmune hepatitis in diverse ethnic populations and geographical regions. Expert Rev Gastroenterol Hepatol 7:365–385

    Article  CAS  PubMed  Google Scholar 

  • Dong WQ, Luo P, Lu DP, Wang H, Wang B (2019) Immunomodulatory effect of schisandrae oil in mouse model of autoimmune hepatitis induced by concanavalin a. Tradit Med Res 4:227–236

    Article  Google Scholar 

  • Eaton JE, Talwalkar JA, Lazaridis KN, Gores GJ, Lindor KD (2013) Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology 145(3):521–536

    Article  CAS  PubMed  Google Scholar 

  • Floreani A, Sun Y, Zou ZS, Li B, Cazzagon N, Bowlus CL, Gershwin ME (2016) Proposed therapies in primary biliary cholangitis. Expert Rev Gastroenterol Hepatol 10(3):371–382

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Górski A, Międzybrodzki R, Borysowski J, Dąbrowska K, Wierzbicki P, Ohams M, Korczak-Kowalska G, Olszowska-Zaremba N, Łusiak-Szelachowska M, Kłak M, Jończyk E, Kaniuga E, Gołaś A, Purchla S, Weber-Dąbrowska B, Letkiewicz S, Fortuna W, Szufnarowski K, Pawełczyk Z, Rogóż P, Kłosowska D (2012) Phage as a modulator of immune responses. Adv Virus Res 83:41–71

    Article  PubMed  CAS  Google Scholar 

  • Górski A, Jończyk-Matysiak E, Łusiak-Szelachowska M, Weber-Dąbrowska B, Międzybrodzki R, Borysowski J (2018) Therapeutic potential of phages in autoimmune liver diseases. Clin Exp Immunol 192:1–6

    Article  PubMed  PubMed Central  Google Scholar 

  • Grant CR, Liberal R, Holder BS, Cardone J, Ma Y, Robson SC, Mieli-Vergani G, Vergani D, Longhi MS (2014) Dysfunctional CD39 POS regulatory T cells and aberrant control of T-helper type 17 cells in autoimmune hepatitis. Hepatology 59:1007–1015

    Article  CAS  PubMed  Google Scholar 

  • Gregorio G (2001) Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 33:544–553

    Article  CAS  PubMed  Google Scholar 

  • Hartemann A, Bensimon G, Payan CA, Jacqueminet S, Bourron O, Nicolas N, Fonfrede M, Rosenzwajg M, Bernard C, Klatzmann D (2013) Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 1:295–305

    Article  CAS  PubMed  Google Scholar 

  • Hennes EM, Oo YH, Schramm C, Denzer U, Buggisch P, Wiegard C, Kanzler S, Schuchmann M, Boecher W, Galle PR, Adams DH, Lohse AW (2008a) Mycophenolate mofetil as second line therapy in autoimmune hepatitis? Am J Gastroenterol 103(12):3063–3070

    Article  CAS  PubMed  Google Scholar 

  • Hennes EM, Zeniya M, Czaja AJ, Parés A, Dalekos GN, Krawitt EL, Bittencourt PL, Porta G, Boberg KM, Hofer H, Bianchi FB, Shibata M, Schramm C, Eisenmann de Torres B, Galle PR, McFarlane I, Dienes HP, Lohse AW (2008b) Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 48:169–176

    Article  PubMed  Google Scholar 

  • Hirschfield GM, Invernizzi P (2011) Progress in the genetics of primary biliary cirrhosis. Semin Liver Dis. https://doi.org/10.1055/s-0031-1276644

  • Huebener P, Schwabe RF (2013) Regulation of wound healing and organ fibrosis by toll-like receptors. Biochim Biophys Acta Mol basis Dis 1832:1005–1017

    Article  CAS  Google Scholar 

  • Imam MH, Sinakos E, Gossard AA, Kowdley KV, Luketic VA, Edwyn Harrison M, McCashland T, Befeler AS, Harnois D, Jorgensen R, Petz J, Keach J, DeCook AC, Enders F, Lindor KD (2011) High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis. Aliment Pharmacol Ther. https://doi.org/10.1111/j.1365-2036.2011.04863.x

  • Karlsen TH, Boberg KM (2013) Update on primary sclerosing cholangitis. J Hepatol 59(3):571–582

    Article  PubMed  Google Scholar 

  • Kortesoja M, Karhu E, Olafsdottir ES, Freysdottir J, Hanski L (2019) Impact of dibenzocyclooctadiene lignans from Schisandra chinensis on the redox status and activation of human innate immune system cells. Free Radic Biol Med 131:309–317

    Article  CAS  PubMed  Google Scholar 

  • Lens S, Leoz M, Nazal L, Bruguera M, Parés A (2014) Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid. Liver Int 34(2):197–203

    Article  CAS  PubMed  Google Scholar 

  • Liberal R, Grant CR (2016) Cirrhosis and autoimmune liver disease: current understanding. World J Hepatol 8:1157

    Article  PubMed  PubMed Central  Google Scholar 

  • Liberal R, Longhi MS, Mieli-Vergani G, Vergani D (2011) Pathogenesis of autoimmune hepatitis. Best Pract Res Clin Gastroenterol 25:653–664

    Article  CAS  PubMed  Google Scholar 

  • Liberal R, Grant CR, Mieli-Vergani G, Vergani D (2013) Autoimmune hepatitis: a comprehensive review. J Autoimmun 41:126–139

    Article  CAS  PubMed  Google Scholar 

  • Liberal R, Grant CR, Holder BS, Cardone J, Martinez-Llordella M, Ma Y, Heneghan MA, Mieli-Vergani G, Vergani D, Longhi MS (2015) In autoimmune hepatitis type 1 or the autoimmune hepatitis-sclerosing cholangitis variant defective regulatory T-cell responsiveness to IL-2 results in low IL-10 production and impaired suppression. Hepatology 62(3):863–875

    Article  CAS  PubMed  Google Scholar 

  • Liberal R, Mieli-Vergani G, Vergani D (2016) Contemporary issues and future directions in autoimmune hepatitis. Expert Rev Gastroenterol Hepatol 10:1163–1174

    Article  CAS  PubMed  Google Scholar 

  • Lim TY, Martinez-Llordella M, Kodela E, Gray E, Heneghan MA, Sanchez-Fueyo A (2018) Low-dose Interleukin-2 for refractory autoimmune hepatitis. Hepatology 68:1649–1652

    Article  PubMed  Google Scholar 

  • Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ (2009) Primary biliary cirrhosis. Hepatology 50:291–308

    Article  PubMed  Google Scholar 

  • Longhi MS, Ma Y, Mieli-Vergani G, Vergani D (2010) Aetiopathogenesis of autoimmune hepatitis. J Autoimmun 34:7–14

    Article  CAS  PubMed  Google Scholar 

  • Lowe D, John S (2018) Autoimmune hepatitis: appraisal of current treatment guidelines. World J Hepatol 10:911–923

    Article  PubMed  PubMed Central  Google Scholar 

  • Makol A, Watt KD, Chowdhary VR (2011) Autoimmune hepatitis: a review of current diagnosis and treatment. Hepat Res Treat. https://doi.org/10.1155/2011/390916

  • Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, Vierling JM (2010) Diagnosis and management of autoimmune hepatitis. Hepatology 51(6):2193–2213

    Article  CAS  PubMed  Google Scholar 

  • Międzybrodzki R, Borysowski J, Kłak M, Jończyk-Matysiak E, Obmińska-Mrukowicz B, Suszko-Pawłowska A, Bubak B, Weber-Dąbrowska B, Górski A (2017) In vivo studies on the influence of bacteriophage preparations on the autoimmune inflammatory process. Biomed Res Int 2017:1–9

    Article  CAS  Google Scholar 

  • Mocan A, Zengin G, Crişan G, Mollica A (2016) Enzymatic assays and molecular modeling studies of Schisandra chinensis lignans and phenolics from fruit and leaf extracts. J Enzyme Inhib Med Chem. https://doi.org/10.1080/14756366.2016.1222585

  • Muratori L, Longhi MS (2013) The interplay between regulatory and effector T cells in autoimmune hepatitis: implications for innovative treatment strategies. J Autoimmun 46:74–80

    Article  CAS  PubMed  Google Scholar 

  • Myers RP, Swain MG, Lee SS, Shaheen AA, Burak KW (2013) B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid. Am J Gastroenterol 108(6):933–941

    Article  CAS  PubMed  Google Scholar 

  • Oo YH, Hubscher SG, Adams DH (2010a) Autoimmune hepatitis: new paradigms in the pathogenesis, diagnosis, and management. Hepatol Int 4:475–493

    Article  PubMed  PubMed Central  Google Scholar 

  • Oo YH, Weston CJ, Lalor PF, Curbishley SM, Withers DR, Reynolds GM, Shetty S, Harki J, Shaw JC, Eksteen B, Hubscher SG, Walker LS, Adams DH (2010b) Distinct roles for CCR4 and CXCR3 in the recruitment and positioning of regulatory T cells in the inflamed human liver. J Immunol 184:2886–2898

    Article  CAS  PubMed  Google Scholar 

  • Parés A (2014) Old and novel therapies for primary biliary cirrhosis. Semin Liver Dis 34(3):341–351

    Article  PubMed  CAS  Google Scholar 

  • Patel A, Seetharam A (2016) Primary biliary cholangitis: disease pathogenesis and implications for established and novel therapeutics. J Clin Exp Hepatol 6:311–318

    Article  PubMed  PubMed Central  Google Scholar 

  • Peiseler M, Sebode M, Franke B, Wortmann F, Schwinge D, Quaas A, Baron U, Olek S, Wiegard C, Lohse AW, Weiler-Normann C, Schramm C, Herkel J (2012) FOXP3+ regulatory T cells in autoimmune hepatitis are fully functional and not reduced in frequency. J Hepatol 57(1):125–132

    Article  CAS  PubMed  Google Scholar 

  • Pimentel-Nunes P, Soares JB, Roncon-Albuquerque R Jr, Dinis-Ribeiro M, Leite-Moreira AF (2010) Toll-like receptors as therapeutic targets in gastrointestinal diseases. Expert Opin Ther Targets 14:347–368

    Article  CAS  PubMed  Google Scholar 

  • Poupon R (2012) Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action. Clin Res Hepatol Gastroenterol 36(Suppl 1):S3–S12. https://doi.org/10.1016/S2210-7401(12)70015-3

    Article  CAS  PubMed  Google Scholar 

  • Prince M, Chetwynd A, Newman W, Metcalf JV, James OF (2002) Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology 123(4):1044–1051

    Article  PubMed  Google Scholar 

  • Sakaguchi S, Yamaguchi T, Nomura T, Ono M (2008) Regulatory T cells and immune tolerance. Cell 133:775–787

    Article  CAS  PubMed  Google Scholar 

  • Sciveres M, Caprai S, Palla G, Ughi C, Maggiore G (2004) Effectiveness and safety of ciclosporin as therapy for autoimmune diseases of the liver in children and adolescents. Aliment Pharmacol Ther 19(2):209–217

    Article  CAS  PubMed  Google Scholar 

  • Soares J-B, Pimentel-Nunes P, Roncon-Albuquerque R, Leite-Moreira A (2010) The role of lipopolysaccharide/toll-like receptor 4 signaling in chronic liver diseases. Hepatol Int 4:659–672

    Article  PubMed  PubMed Central  Google Scholar 

  • Soares PA, Nascimento CO, Porto TS, Correia MT, Porto AL, Carneiro-da-Cunha MG (2011) Purification of a lectin from Canavalia ensiformis using PEG-citrate aqueous two-phase system. J Chromatogr B Anal Technol Biomed Life Sci 879(5–6):457–460

    Article  CAS  Google Scholar 

  • Speletas M, Argentou N, Germanidis G, Vasiliadis T, Mantzoukis K, Patsiaoura K, Nikolaidis P, Karanikas V, Ritis K, Germenis AE (2011) Foxp3 expression in liver correlates with the degree but not the cause of inflammation. Mediat Inflamm. https://doi.org/10.1155/2011/827565

  • Strassburg CP, Manns MP (2011) Therapy of autoimmune hepatitis. Best Pract Res Clin Gastroenterol 25(6):673–687

    Article  CAS  PubMed  Google Scholar 

  • Szopa A, Kokotkiewicz A, Bednarz M, Luczkiewicz M, Ekiert H (2017) Studies on the accumulation of phenolic acids and flavonoids in different in vitro culture systems of Schisandra chinensis (Turcz.) Baill. Using a DAD-HPLC method. Phytochem Lett. https://doi.org/10.1016/j.phytol.2016.10.016

  • Tabibian JH, Weeding E, Jorgensen RA, Petz JL, Keach JC, Talwalkar JA, Lindor KD (2013) Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis—a pilot study. Aliment Pharmacol Ther 37(6):604–612

    Article  CAS  PubMed  Google Scholar 

  • Takahashi K, Murakami M, Hosaka K, Kikuchi H, Oshima Y, Kubohara Y (2009) Regulation of IL-2 production in Jurkat cells by Dictyostelium-derived factors. Life Sci 85(11–12):438–443

    Article  CAS  PubMed  Google Scholar 

  • Than NN, Oo YH (2015) A concise review of autoimmune liver diseases. In: Autoimmunity—pathogenesis, clinical aspects and therapy of specific autoimmune diseases. InTech

    Google Scholar 

  • Triantos CK, Koukias NM, Nikolopoulou VN, Burroughs AK (2011) Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis. Aliment Pharmacol Ther. https://doi.org/10.1111/j.1365-2036.2011.04822.x

  • Trivedi PJ, Hirschfield GM (2012) Review article: overlap syndromes and autoimmune liver disease. Aliment Pharmacol Ther 36(6):517–533

    Article  CAS  PubMed  Google Scholar 

  • Van Belleghem JD, Clement F, Merabishvili M, Lavigne R, Vaneechoutte M (2017) Pro- and anti-inflammatory responses of peripheral blood mononuclear cells induced by Staphylococcus aureus and Pseudomonas aeruginosa phages. Sci Rep 7:8004

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Wang P, Zheng S (2013) Regulatory T cells and B cells: implication on autoimmune diseases. Int J Clin Exp Pathol 6:2668

    PubMed  PubMed Central  Google Scholar 

  • Washington MK (2007) Autoimmune liver disease: overlap and outliers. Mod Pathol 20:S15–S30

    Article  CAS  PubMed  Google Scholar 

  • Weiler-Normann C, Schramm C, Quaas A, Wiegard C, Glaubke C, Pannicke N, Möller S, Lohse AW (2013) Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis. J Hepatol 58(3):529–534

    Article  CAS  PubMed  Google Scholar 

  • Werner M, Prytz H, Ohlsson B, Almer S, Björnsson E, Bergquist A, Wallerstedt S, Sandberg-Gertzén H, Hultcrantz R, Sangfelt P, Weiland O, Danielsson A (2008) Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: a nationwide study. Scand J Gastroenterol 43:1232–1240

    Article  PubMed  Google Scholar 

  • Wong RJ, Gish R, Frederick T, Bzowej N, Frenette C (2012) The impact of race/ethnicity on the clinical epidemiology of autoimmune hepatitis. J Clin Gastroenterol 46:155–161

    Article  PubMed  Google Scholar 

  • Yeoman AD, Longhi MS, Heneghan MA (2010) Review article: the modern management of autoimmune hepatitis. Aliment Pharmacol Ther 31(8):771–787

    CAS  PubMed  Google Scholar 

  • Yimam KK, Bowlus CL (2014) Diagnosis and classification of primary sclerosing cholangitis. Autoimmun Rev 13(4–5):445–450

    Article  CAS  PubMed  Google Scholar 

  • Zachou K, Gatselis N, Papadamou G, Rigopoulou EI, Dalekos GN (2011) Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients. J Hepatol 55(3):636–646

    Article  CAS  PubMed  Google Scholar 

  • Zhang X, Wei HX, Rui S, Wei H, Tian Z (2010) Opposite effects of high and low doses of interleukin-2 on T cell-mediated hepatitis in mice (interleukin-2 on hepatitis). Hepatol Int 4(3):641–648

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biotechnology, GITAM Institute of Technology, GITAM Deemed to be University, Visakhapatnam, India

    Kaligotla Venkata Subrahmanya Anirudh & Prameela Kandra

Authors
  1. Kaligotla Venkata Subrahmanya Anirudh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prameela Kandra
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Computer Application, Nehru Gram Bharati (Deemed to be University), Prayagraj, Uttar Pradesh, India

    Rajesh K. Kesharwani

  2. Faculty of B. Pharmacy, CSM Group of Institutions, Prayagraj, Uttar Pradesh, India

    Raj K. Keservani

  3. Department of Pharmacy, School of Medical and Allied Sciences, GD Goenka University, Gurugram, Haryana, India

    Anil K. Sharma

Ethics declarations

The authors declare that there are no competing interests.

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Anirudh, K.V.S., Kandra, P. (2022). Immunomodulators and Autoimmune Liver Diseases. In: Kesharwani, R.K., Keservani, R.K., Sharma, A.K. (eds) Immunomodulators and Human Health. Springer, Singapore. https://doi.org/10.1007/978-981-16-6379-6_8

Download citation

Publish with us

Policies and ethics

Search

Navigation